Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today shared positive updated results from inMMyCAR, the ongoing first-in-human Phase 1 study of KLN-1010 in patients with relapsed and refractory multiple myeloma (RRMM), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Kelonia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KLN-1010, an in vivo BCMA CAR-T Therapy for Relapsed and Refractory Multiple Myeloma
Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for KLN-1010 for the treatment of patients with relapsed and refractory multiple myeloma.
Kelonia Therapeutics Presents First-in-Human Data From Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting
Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today shared first-in-human data from the ongoing inMMyCARTM study, a Phase 1 clinical trial evaluating KLN-1010, a novel in vivo gene therapy that generates anti-BCMA CAR-T cells in patients with relapsed and refractory multiple myeloma, in a late-breaking oral presentation at the American Society of Hematology (ASH) 2025 Annual Meeting in Orlando, Florida.
Kelonia Therapeutics Announces Late-Breaking Oral Presentation of First-in-Human Data from in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting
Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced that its first results from the ongoing inMMyCAR study, a Phase 1 clinical trial evaluating KLN-1010, a novel in vivo gene therapy that generates anti-BCMA CAR-T cells in patients with relapsed and refractory multiple myeloma, will be presented in a late-breaking oral presentation at the American Society of Hematology (ASH) 2025 Annual Meeting in Orlando, Florida.
Kelonia Therapeutics Doses First Patient in Phase 1 inMMyCAR Study Evaluating in vivo CAR T-Cell Therapy for Relapsed and Refractory Multiple Myeloma
Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, today announced that the first patient has been dosed in the inMMyCAR study, a Phase 1 clinical trial evaluating KLN-1010, a novel in vivo gene therapy that generates anti-BCMA CAR-T cells, in patients with relapsed and refractory multiple myeloma.
Kelonia Therapeutics to Present iGPS® Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting
Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced new preclinical data of its in vivo Gene Placement System (iGPS®) will be highlighted at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place on May 13-17, 2025, in New Orleans, Louisiana.
Kelonia Therapeutics to Participate in Upcoming Scientific Conferences
Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced preclinical data from its lead in vivo CAR-T cell therapeutic candidate KLN-1010 in multiple myeloma that will be highlighted at two upcoming scientific conferences – the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, taking place on May 7-11, 2024, in Baltimore, Maryland, and the Protein Engineering Summit (PEGS) Boston Summit 2024, taking place on May 13-17, 2024, in Boston.
